Abbott Laboratories $ABT Shares Sold by Shelton Wealth Management LLC

Shelton Wealth Management LLC decreased its position in Abbott Laboratories (NYSE:ABT) by 78.9% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 2,164 shares of the healthcare product maker’s stock after selling 8,084 shares during the quarter. Shelton Wealth Management LLC’s holdings in Abbott Laboratories were worth $271,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in the company. Whittier Trust Co. raised its stake in Abbott Laboratories by 0.6% in the 4th quarter. Whittier Trust Co. now owns 404,634 shares of the healthcare product maker’s stock valued at $51,704,000 after purchasing an additional 2,248 shares during the last quarter. Iams Wealth Management LLC raised its stake in Abbott Laboratories by 3.3% in the 4th quarter. Iams Wealth Management LLC now owns 16,158 shares of the healthcare product maker’s stock valued at $2,025,000 after purchasing an additional 515 shares during the last quarter. CM Wealth Advisors LLC raised its stake in Abbott Laboratories by 117.7% in the 4th quarter. CM Wealth Advisors LLC now owns 13,747 shares of the healthcare product maker’s stock valued at $1,722,000 after purchasing an additional 7,431 shares during the last quarter. Private Trust Co. NA raised its stake in Abbott Laboratories by 3.4% in the 4th quarter. Private Trust Co. NA now owns 24,615 shares of the healthcare product maker’s stock valued at $3,084,000 after purchasing an additional 801 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its stake in Abbott Laboratories by 13.4% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 365,276 shares of the healthcare product maker’s stock valued at $45,765,000 after purchasing an additional 43,195 shares during the last quarter. Institutional investors and hedge funds own 75.18% of the company’s stock.

Key Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Q1 results narrowly beat expectations: adjusted EPS $1.15 vs. $1.14 consensus and revenue $11.16B (up 7.8% y/y), supported by cancer-diagnostics and medical-device strength. Abbott first-quarter results beat on cancer diagnostics, medical device strength
• Positive Sentiment: Exact Sciences acquisition expands Abbott into high-growth oncology diagnostics and is presented as strategic long-term growth even though it creates near-term EPS dilution. Abbott Reports First-Quarter 2026 Results; Updates Guidance to Reflect Acquisition of Exact Sciences
• Positive Sentiment: Broker support and insider activity: RBC Capital reaffirmed its buy rating and company insiders added shares, both signals of continued institutional/management confidence. RBC Capital Reaffirms Their Buy Rating on Abbott Laboratories (ABT) Abbott Laboratories Insiders Added US$3.10m Of Stock To Their Holdings
• Negative Sentiment: Guidance cut and dilution: Abbott lowered FY2026 adjusted EPS to $5.38–$5.58 (includes ~$0.20/share dilution from Exact Sciences) and Q2 EPS to $1.25–$1.31, below Street expectations — the guidance hit is the primary reason investors sold shares. Abbott stock slips on guidance cut, ranks 10th in healthcare equipment Quant ratings
• Negative Sentiment: Margin pressure and weak Nutrition segment: management flagged margin compression and a prolonged slump in nutrition sales (plus a milder flu season that hurt consumer-test volumes), which weigh on near-term profit recovery. Abbott Stock Falls Despite Q1 Earnings & Revenue Beat Abbott Laboratories Cuts Outlook, Says Mild Flu Season Hurt Sales
• Negative Sentiment: Market reaction: Despite the beat, investors focused on the weaker guide and merger-related costs, sending the stock lower (coverage pieces and commentaries explain the selloff). Why Abbott Laboratories Stock Tumbled on Thursday

Abbott Laboratories Stock Performance

Shares of ABT opened at $95.08 on Friday. The firm has a 50-day moving average price of $108.17 and a 200 day moving average price of $119.01. The firm has a market capitalization of $165.59 billion, a PE ratio of 25.56, a P/E/G ratio of 1.62 and a beta of 0.79. The company has a quick ratio of 1.18, a current ratio of 1.58 and a debt-to-equity ratio of 0.19. Abbott Laboratories has a 52-week low of $93.92 and a 52-week high of $139.06.

Abbott Laboratories (NYSE:ABT) last announced its earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.14 by $0.01. The firm had revenue of $11.16 billion during the quarter, compared to analyst estimates of $10.99 billion. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.73%. Abbott Laboratories’s revenue was up 7.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.09 EPS. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. On average, sell-side analysts anticipate that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be given a $0.63 dividend. The ex-dividend date is Wednesday, April 15th. This represents a $2.52 annualized dividend and a yield of 2.7%. Abbott Laboratories’s payout ratio is 67.74%.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on ABT shares. The Goldman Sachs Group cut their target price on Abbott Laboratories from $140.00 to $121.00 and set a “buy” rating on the stock in a research report on Wednesday, April 8th. Weiss Ratings cut Abbott Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Monday, January 26th. Argus reduced their price objective on Abbott Laboratories from $150.00 to $140.00 in a research note on Tuesday, January 27th. Citigroup reduced their price objective on Abbott Laboratories from $140.00 to $136.00 and set a “buy” rating on the stock in a research note on Wednesday, March 11th. Finally, Sanford C. Bernstein reduced their price objective on Abbott Laboratories from $154.00 to $125.00 and set an “outperform” rating on the stock in a research note on Friday, January 23rd. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $134.00.

Insider Transactions at Abbott Laboratories

In other Abbott Laboratories news, SVP Eric Shroff sold 709 shares of the business’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $81,946.22. Following the sale, the senior vice president directly owned 39,164 shares in the company, valued at approximately $4,526,575.12. The trade was a 1.78% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Mary K. Moreland sold 613 shares of the business’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $70,850.54. Following the completion of the sale, the executive vice president owned 104,291 shares in the company, valued at approximately $12,053,953.78. This trade represents a 0.58% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 3,055 shares of company stock valued at $353,097 in the last quarter. 0.46% of the stock is owned by company insiders.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.